ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1550

Long-Term Outcomes of Patients with Reversible Cerebral Vasoconstriction Syndromes (RCVS)

Seby John1, Leonard H. Calabrese2, Stewart Tepper3, Mark Stillman3, Ken Uchino1 and Rula Hajj-Ali3, 1Neurology, Cleveland Clinic Foundation, Cleveland, OH, 2Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Neurologic involvement and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

RCVS is a syndrome characterized by acute onset of severe headaches, with or without neurologic deficit with evidence of reversible cerebral vasoconstriction. Natural history and long term outcome of RCVS has not been thoroughly investigated. To date, three main series of RCVS have been reported and long term outcomes were not readily available.

Objectives: i) To assess long term neurologic outcome of patients with RCVS using validated outcome measures for stroke and headache  ii) To determine the impact of RCVS on patient’s health related quality of life (QoL). 

Methods:

After approval from the institutional review board, prospective cohort analysis of patients recruited from our RCVS database registry was conducted. Validated questionnaires were mailed to the patients on a one-time-basis.  The forms included: Headache screening questionnaire, Headache Impact Test-6 (HIT-6), Barthel index (BI), Patient Health Questionnaire (PHQ-9) and European QoL Questionnaire (EQ-5D-5L).

Results:

A total of 57 patients were present in the RCVS registry. Of these patients, 3 refused to participate in the study, 26 were inaccessible or lost to follow-up, 11 agreed to participate but never returned the forms, and 17 returned the questionnaires (5 incomplete). Mean follow-up time from diagnosis to answering questionnaires was 112 months (range 10-254 months). Of the 17 patients, 8 (47%) continued to have headaches, but majority (88%) reported improvement in the character of headaches with only 1 patient having worsening. 3 (38%) patients reported that the headaches were similar to the initial headache during onset of RCVS. Headache impact on life as measured by the HIT-6 showed that only 2 patients (17%) had a severe impact (HIT score > 60), while 3 patients each (25%) reported substantial impact (56-59) or some impact (50-55); and 4 (33%) reported no impact (<50). The mean MIDAS score was 11.83 and only 2 (17%) had severe disabling headaches (MIDAS score > 21).  13(93%) patients were independent per BI scores > 85 (8 patients scored 100). EQ-5D-5L measurements showed that 9 (69%), 11 (85%) and 9(69%) patients had no problems with mobility, self-care and leisure respectively. However, 10 (77%) and 7(54%) patients had slight to severe problems with pain and anxiety respectively.  Scoring per the PHQ-9 questionnaire revealed that only 1 (7%) patient had severe depression (PHQ score 20-27), while 7(50%), 3(21%), 1(7%) and 3(21%) patients had no/minimal (0-4), mild (5-9), moderate (10-14) and moderately severe (15-19) depression. 

Conclusion:

This is the first study looking at the long term outcomes of patients with RCVS.  Although limited by small numbers, preliminary data suggests that patients with RCVS have favorable outcomes both in terms of headaches and stroke. Although close to half (47%) of patients continued to have chronic headaches, most had improved in character with only 17% reporting severe headache by MIDAS and HIT-6 scoring. Majority of patients were also independent (93%) and had no problems with mobility or self-care, but pain and anxiety decreased the QoL. Severe and moderately-severe depression was present in 28% of patients.  Additional studies are needed to determine if similar results are observed in other RCVS patients.


Disclosure:

S. John,
None;

L. H. Calabrese,
None;

S. Tepper,

Allergan, ATI, BristolMyerSquibb, DepoMed, GSK, MAP, Merck, NuPathe, and Zogenix,

2,

ATI,

1;

M. Stillman,
None;

K. Uchino,
None;

R. Hajj-Ali,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcomes-of-patients-with-reversible-cerebral-vasoconstriction-syndromes-rcvs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology